Imcheck Therapeutics

The company develops immunotherapeutic antibodies that target the butyrophilin and butyrophilin-like superfamily of checkpoint molecules to modulate the immune system. Its pipeline focuses on treatments for cancer, infectious diseases, and autoimmune diseases, specifically utilizing gamma-delta T cells. The firm was recently acquired by Ipsen to expand its oncology portfolio.